Executive Summary
CardioCalm is a specialized digital therapeutic platform designed to address the debilitating condition of cardiophobia—the intense, unfounded fear of having a serious heart condition, often accompanied by real physical symptoms like palpitations and dizziness. Current solutions often lead to expensive, unnecessary medical testing, failing to address the root psychological cause. Our solution provides a structured, evidence-based digital program combining Cognitive Behavioral Therapy (CBT), biofeedback, and symptom validation exercises to break the anxiety-symptom feedback loop.
Our target market consists of individuals aged 25-55 who frequently visit emergency rooms or cardiologists for reassurance, a significant and underserved segment within the broader health anxiety market estimated to be worth over $500 million annually in unnecessary healthcare spending in the US alone. We plan to generate revenue through a subscription model targeted both at individual users and, eventually, through partnerships with cardiology practices for patient referrals.
We project reaching a monthly recurring revenue of $50,000 to $80,000 within 18 months, driven by a strong focus on digital marketing and clinical validation. CardioCalm offers a scalable, accessible, and cost-effective alternative to traditional therapy for this specific, high-stress health anxiety subset, positioning us for rapid adoption.
The Problem
The core problem is chronic cardiophobia, a specific subset of health anxiety (hypochondriasis), affecting millions globally. Individuals experience genuine physical sensations (e.g., premature ventricular contractions, rapid heart rate, shortness of breath) which, due to anxiety, they catastrophize as life-threatening cardiac events. This leads to a vicious cycle: symptom flares trigger intense fear, which in turn amplifies the physical symptoms, forcing repeated visits to cardiologists and emergency departments for reassurance (the 'reassurance-seeking behavior'). This cycle is exhausting, financially draining, and results in clinical burden, as medical testing repeatedly comes back normal, yet the patient's distress remains high because the underlying anxiety has not been treated. Existing solutions are either generalized anxiety apps lacking specific cardiophobia protocols or costly, in-person therapy appointments that patients often delay due to symptom-related anxiety.
Our Solution
CardioCalm is a proprietary mobile application that delivers a structured, 12-week digital therapeutic program focused entirely on managing cardiophobia. Key features include: 1) Symptom Validation Library: Explaining common benign cardiac sensations in a reassuring, educational manner. 2) Personalized CBT Modules: Directly addressing catastrophic thinking patterns related to heart health. 3) Biofeedback Integration: Utilizing smartphone sensors (like heart rate monitors if available, or manual input) to track physiological responses during anxiety spikes, teaching users to regulate their autonomic nervous system. 4) Graded Exposure Protocol: Safely guiding users to tolerate physical sensations without resorting to reassurance-seeking. Our uniqueness lies in the hyper-focus on the cardiac context, providing clinically informed, accessible intervention that bridges the gap between medical clearance and psychological treatment.
Ready to Take Action?
CardioCalm is positioned at the critical intersection of scalable digital mental health and high-need medical reassurance-seeking behavior. We invite investors and clinical partners to join us in providing an accessible, validated path to freedom from cardiophobia, capitalizing on a clear market failure to treat the psychological root of these physical symptoms.